RESOURCES: PUBLICATIONS
CHANGING THE FUTURE
Publications
- Satterfield, Brent C. (2013) Cooperative Primers; 2.5 Million–Fold Improvement in the Reduction of Nonspecific Amplification. The Journal of Molecular Diagnostics, Vol: 16, Issue: 2, Page: 163-73. DOI: https://doi.org/10.1016/j.jmoldx.2013.10.004
- Garcia, Rebecca A. et al. (2015). Dengue Virus: Another Type of Immigrant, The Journal for Nurse Practitioners, Volume: 11, Issue: 1, Page: 34 – 40. DOI: https://doi.org/10.1016/j.nurpra.2014.10.019
- Co-Diagnostics Whitepaper: Evaluating Differences in Rates of Positives for COVID-19 Testing from TestUtah (June 5, 2020)
- Co-Diagnostics Whitepaper: CoPrimer Based rRT-PCR Detection of SARS-CoV-2 Directly from Saliva (November 10, 2020)

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2018 Co-Diagnostics, Inc. • All Rights Reserved.
LATEST NEWS RELEASE
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share
Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly...

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2018 Co-Diagnostics, Inc. • All Rights Reserved.